Revvity, 6FRAHPAG, HTRF CD32a (131H) Cellular Binding Kit, 100 Assay Points

Overview
The CD32a (FcgRIIa, H131) cellular binding assay is a simple and robust test to monitor binding of the IgG Fc region to the human CD32a receptorin live cells and to select the most potent antibody for use in Antibody-Dependent Cell-Phagocytosis (ADCP). Two separate CD32a assays are available to specifically target the H131 or R131 variants. These assays, based on our innovative Tag-lite technology, can easily be automated to create a high-throughput solution for predicting ADCP.
HTRF assays offer many advantages over other technologies:

Homogeneous add-and-read format
No wash steps
Low background
Straightforward miniaturization from 96- or 384-well microplates to high density assay formats such as 384-well low volume and 1536-well plates
Stable signal, providing flexibility in time of readout or size of assays
How it works
Assay principle
The CD32a receptor cellular binding assay is a competitive assay involving HEK293 cells expressing a specific CD32a variant conjugated to Lumi4-terbium Cryptate, and human IgG1 labelled with d2. The unlabeled antibody or Fc tagged drug competes with the d2 labelled IgG1 for binding to the receptor, resulting in a decrease of FRET signal. 

Assay protocol
The CD32a receptor cellular binding assays (FcgIIa H131 or R131) present only 1 incubation step after reagents distribution. Lumi4-terbium Cryptate pre-labelled cells are dispensed, followed by the addition of IgG1 labelled with d2 and the sample. After 2h incubation at RT, the signal can be read. Application-Protein Quantification
Brand-HTRF
Detection Modality-HTRF
Product Group-Kit
Sample Volume-5 µL
Shipping Conditions-Shipped in Dry Ice
Target Class-Biologics
Technology-TR-FRET
Therapeutic Area-Cardiovascular Infectious Diseases Metabolism/Diabetes NASH/Fibrosis Neuroscience Rare Diseases
Unit Size-100 assay points